─Appoints Ilan Vaknin, PhD, as Vice President
of Research & Development and Christina
Crater, MD, as Vice President of Clinical
Development─
TEL
AVIV, Israel, Aug. 12,
2022 /PRNewswire/ -- Chemomab Therapeutics, Ltd.
(Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company
focused on the discovery and development of innovative therapeutics
for fibrotic and inflammatory diseases with high unmet need, today
announced the addition of Ilan
Vaknin, PhD, MBA, as Vice President of Research &
Development and Christina Crater,
MD, as Vice President of Clinical Development.
"Chemomab is distinguished by the strength of its science, and
we are fortunate these two premiere scientific and medical
professionals are assuming critical roles as we progress the
development of CM-101, our pipeline in a product with breakthrough
potential," said Dale Pfost, PhD,
Chief Executive Officer of Chemomab. "We are preparing to report
topline results from our Phase 2 trial in liver fibrosis patients
later this year, we are expanding our Phase 2 trial of CM-101 in
primary sclerosing cholangitis, we will soon be launching a Phase 2
biological proof of concept trial in systemic sclerosis, and we are
assessing potential new indications for CM-101 in other
fibro-inflammatory disorders. Dr. Vaknin's more than 20 years of
broad-ranging experience in immunology, bioassay development, and
antibody R&D and manufacturing will be invaluable as we work to
accelerate advancement of our pipeline programs."
Dr. Vaknin brings Chemomab more than two decades of
biotechnology drug discovery and development experience in
immunology, antibody development, translational research and
bioassay development, including more than a decade in senior
science roles at Compugen, Ltd. He most recently served as Director
of Preclinical Bioassays, where he oversaw preclinical bioassay
development and related activities, while working with
computational and validation teams to support discovery of novel
drug targets and biomarkers. Prior to Compugen, Dr. Vaknin served
as Chief Technology Officer at Active P, where he led the
development of orally available therapeutic peptides. Earlier in
his career, he served as External Scientific Consultant for the
Department of Neurobiology at Israel's Weizmann Institute of Science. Dr.
Vaknin holds a PhD in immunology and a BA in life sciences from The
Hebrew University of Jerusalem, where
he also received an MBA in finance.
Dr. Pfost continued, "Dr. Crater's extensive background in
medical affairs and clinical trial design and execution across a
broad range of therapeutic indications will be instrumental as we
ramp up our clinical activities. She has highly relevant experience
leading clinical research programs in immuno-inflammation and
orphan diseases. Her decade as a front-line physician gives her a
first-hand appreciation for the essential roles of patients and
physicians in the successful development of new therapies. I am
delighted to welcome Ilan and Chris to the Chemomab senior team at
this exciting time in our evolution."
Dr. Crater has served as a medical monitor, safety physician,
therapeutic expert and study director in all phases of clinical
development, including extensive experience in data quality and
safety monitoring. Her career spans working in-house at
pharmaceutical and biotechnology firms, as well as at major
clinical research organizations (CROs). Previously Dr. Crater
served as Senior Clinical Trial Physician at Bristol-Myers Squibb,
where she was responsible for the review and interpretation of
clinical data while contributing to strategic decisions on clinical
study design and asset advancement. Dr. Crater also served in
senior clinical development roles with PRA Health Sciences and
PAREXEL International. Earlier in her career, Dr. Crater worked as
an internal medicine physician. She received an MD degree from the
University of Tennessee and holds a BS
from Rhodes College. Dr. Crater is
board certified in Internal Medicine.
About Chemomab Therapeutics
Chemomab is a clinical-stage biotechnology company focusing
on the discovery and development of innovative therapeutics for
fibrotic and inflammatory diseases with high unmet need. Based on
the unique and pivotal role of the soluble protein CCL24 in
promoting fibrosis and inflammation, Chemomab developed CM-101, a
monoclonal antibody designed to bind and block CCL24 activity.
CM-101 has demonstrated the potential to treat multiple severe and
life-threatening fibrotic and inflammatory diseases. It is
currently in Phase 2 trials for primary sclerosing cholangitis and
liver fibrosis, with a Phase 2 trial in systemic sclerosis expected
to begin in late 2022. For more information,
visit chemomab.com.
Forward Looking Statements
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act. These
forward-looking statements include, among other things, statements
regarding the clinical development pathway for CM-101; the future
operations of Chemomab and its ability to successfully initiate and
complete clinical trials and achieve regulatory milestones; the
nature, strategy and focus of Chemomab; the development and
commercial potential and potential benefits of any product
candidates of Chemomab; and that the product candidates have the
potential to address high unmet needs of patients with serious
fibrosis-related diseases and conditions. Any statements contained
in this communication that are not statements of historical fact
may be deemed to be forward-looking statements. These
forward-looking statements are based upon Chemomab's current
expectations. Forward-looking statements involve risks and
uncertainties. Because such statements deal with future events and
are based on Chemomab's current expectations, they are subject to
various risks and uncertainties and actual results, performance or
achievements of Chemomab could differ materially from those
described in or implied by the statements in this presentation,
including: risks related to Chemomab's ability to effectively
implement the revised clinical strategy and its ability to achieve
the anticipated results; risks related to the projections and
associated benefits in pursuing the contemplated changes to the
clinical strategy; risks associated with the ongoing transitions of
certain of our executive officers; the uncertain and time-consuming
regulatory approval process; risks related to Chemomab's ability to
correctly manage its operating expenses and its expenses;
Chemomab's plans to develop and commercialize its product
candidates, focusing on CM-101; the timing of initiation of
Chemomab's planned clinical trials; the timing of the availability
of data from Chemomab's clinical trials including any potential
delays associated with Chemomab's contemplated revised clinical
strategy; the timing of any planned investigational new drug
application or new drug application; Chemomab's plans to research,
develop and commercialize its current and future product
candidates; the clinical utility, potential benefits and market
acceptance of Chemomab's product candidates; Chemomab's
commercialization, marketing and manufacturing capabilities and
strategy; Chemomab's ability to protect its intellectual property
position; and the requirement for additional capital to continue to
advance these product candidates, which may not be available on
favorable terms or at all. Additional risks and uncertainties
relating to Chemomab's and its business can be found under the
caption "Risk Factors" and elsewhere in Chemomab's filings and
reports with the SEC. Chemomab expressly disclaims any obligation
or undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change
in Chemomab's expectations with regard thereto or any change in
events, conditions or circumstances on which any such statements
are based, except to the extent required by applicable law.
Contacts:
|
|
|
Media:
|
Investor
Relations:
|
Barbara
Lindheim
|
Irina
Koffler
|
Chemomab
Therapeutics
|
LifeSci Advisors,
LLC
|
Consulting Vice
President
|
Phone:
+1-917-734-7387
|
Investor & Public
Relations,
|
ir@chemomab.com
|
Strategic
Communications
|
Phone:
+1-917-355-9234
|
barbara@chemomab.com
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/chemomab-adds-highly-experienced-executives-further-strengthening-its-rd-and-clinical-capabilities-301604869.html
SOURCE Chemomab Therapeutics, Ltd.